<--- Back to Details
First PageDocument Content
Dispute resolution / Conflict / Personality tests / Conflict management / Ethnic conflict / Organization development / Tyrosine-kinase inhibitor / Change management / ThomasKilmann Conflict Mode Instrument
Date: 2016-04-19 00:14:46
Dispute resolution
Conflict
Personality tests
Conflict management
Ethnic conflict
Organization development
Tyrosine-kinase inhibitor
Change management
ThomasKilmann Conflict Mode Instrument

The TKI Tool More Than Conflict Management ce n

Add to Reading List

Source URL: www.cppasiapacific.com

Download Document from Source Website

File Size: 852,95 KB

Share Document on Facebook

Similar Documents

The TKI Tool More Than Conflict Management ce n

The TKI Tool More Than Conflict Management ce n

DocID: 1rdnE - View Document

ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced

DocID: 1qm1i - View Document

TECHNOLOGY OFFER  A COBALT-BASED STRATEGY FOR TUMOUR TARGETING OF EGFR-INHIBITORS BACKGROUND The development of receptor tyrosine-kinase inhibitors (TKIs) in recent

TECHNOLOGY OFFER A COBALT-BASED STRATEGY FOR TUMOUR TARGETING OF EGFR-INHIBITORS BACKGROUND The development of receptor tyrosine-kinase inhibitors (TKIs) in recent

DocID: 1pWe8 - View Document

Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra

Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra

DocID: 1pvTL - View Document

Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis

Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis

DocID: 1p0SG - View Document